Primary study · included by 2 reviews

1.2% Rosuvastatin and 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in the Treatment of Class II Furcation Defects: A Randomized Controlled Clinical Trial.

Garg and Pradeep 2017 · Garg Shruti, Pradeep A R · Journal of periodontology · 2017

Included by

Evidence on pharmacological agents for treating bony defects in chronic periodontitis: A network meta-analysis.
Non-Cochrane · intervention · 2025 · cited as Garg 2017 · Table 1; References

The review does not say which of its outcomes this study informs.

Adjunctive Use of Locally Delivered Statins in Periodontal Therapy and Pre-Implant Bone Regeneration: A Systematic Review and Meta-Analysis.
Non-Cochrane · intervention · 2026 · cited as Garg 2017 · Figures 2-4; Tables 4-5 and reference list
Outcome this study informsPooled effectEvidenceCertainty
Clinical attachment level (CAL), change from baseline (mm)
SRP plus locally delivered 1.2% atorvastatin gel vs SRP alone (placebo gel or no gel) · 6 months
MD 1.70 [1.22, 2.19]6 studies · 332 participantsGRADE not reported
Probing pocket depth (PPD), change from baseline (mm)
SRP plus locally delivered 1.2% rosuvastatin gel vs SRP alone (placebo gel or no gel) · 6 months
MD 1.91 [1.35, 2.48]4 studies · 211 participantsGRADE not reported
Clinical attachment level (CAL), change from baseline (mm)
SRP plus locally delivered 1.2% rosuvastatin gel vs SRP alone (placebo gel or no gel) · 6 months
MD 1.94 [1.33, 2.56]4 studies · 211 participantsGRADE not reported
Probing pocket depth (PPD), change from baseline (mm)
SRP plus locally delivered 1.2% atorvastatin gel vs SRP alone (placebo gel or no gel) · 6 months
MD 1.39 [0.99, 1.79]6 studies · 332 participantsGRADE not reported

2 including reviews in total.